MEDIAN Technologies to propose nomination of Dr. Kapil Dhingra to its Board of Directors

26 October 2012, Sophia Antipolis, France

Dr. Kapil Dhingra will bring to the board his strategic expertise, vision, and experience of the global biopharma industry with an emphasis on the oncology therapeutic area.

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, announced today that the Board of Directors, chaired by Fredrik Brag, CEO, has proposed to appoint Mr. Kapil Dhingra as a new director for a period of 3 years. This decision was made at the Board’s meeting on October 4 and will be put on the agenda of the next shareholders’ meeting.

“Kapil Dhingra will bring us his unique strategic expertise, vision and experience of the global biopharma industry, said Fredrik Brag, CEO of MEDIAN and Chairman. “Kapil has a vast experience in bringing innovations to the drug development process in oncology. His knowledge and support will contribute to further enhance MEDIAN growth strategy, in particular as regards to the advanced imaging services that we bring to top tiers Pharmas and Biotechs. We are very proud to have him joining our Board”, Fredrik Brag added.

Accurate and consistent evaluation of tumors is crucial to the management of patients with cancer and in clinical trials of new drugs and represents a major unmet technology need in oncology today”, said Kapil Dhingra “The solutions provided by the MEDIAN platform can greatly enhance interpretation and management of images.  The ability to obtain high quality and accurate lesion assessment in near-real-time can significantly enhance the efficiency of clinical trials of new drugs.”

Dr. Dhingra founded KAPital Consulting LLC in 2008 to help biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of advances in oncology. From 1999 to 2008, he served in positions of increasing responsibility at Roche including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the Oncology Clinical Development Group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center where he led a successful laboratory as well as clinical research program.

Throughout his industry career, Dr. Dhingra held an active faculty appointment at Indiana University School of Medicine from 1997 to 1999, and more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.

Dr. Dhingra holds an M.B., B.S. (equivalent to US M.D.) degree from the All India Institute of Medical Sciences (AIIMS), and has performed postgraduate work at the AIIMS, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx NY and Emory University School of Medicine, Atlanta GA.  He is Board-certified in Internal Medicine and Medical Oncology.

Dr. Dhingra is currently an advisor to and/or member of the Board of Directors of several biotechnology and pharmaceutical companies and organizations. He has previously served on the Boards of several successful biotech companies, including Biovex and Micromet, which were acquired by major pharmaceutical companies.